Evidence Summary: Super-oxidised solutions for chronic wounds

January 2020
Author: Assoc. Prof. Emily Haesler, PhD
Wound Healing and Management Centre, Curtin University (WHAM@Curtin)

DOI https://doi.org/10.33235/wpr.28.3.145-147

CLINICAL QUESTION
What is the best available evidence for using super-oxidised solutions (SOSs) to reduce infection and promote healing in chronic wounds in all populations?

SUMMARY
Super-oxidised solutions are a low cost topical antiseptic option for chronic wounds. Antibacterial, antimicrobial and anti-fungal properties of SOSs have been established in laboratory research (Level 5). Level 1 evidence from a systematic review and a randomised controlled trial (RCT) showed SOS was as effective as povidone iodine in reduction microbial bioburden. Level 1 evidence from a systematic review and four RCTs showed SOS was superior to both povidone iodine and saline for promoting healing, established using different outcome measures (e.g. percent of wounds healed, mean reduction in wound surface area, rate of healing and increase in granulation tissue). This evidence, together with additional Level 2 and Level 4 evidence, supported a Grade B recommendation (a weak recommendation).10

CLINICAL PRACTICE RECOMMENDATIONS
All recommendations should be applied with consideration to the wound, the patient, the health professional and the clinical context.

Super-oxidised solutions could be used to reduce local infection and promote healing in chronic wounds, particularly diabetic foot ulcers (Grade B).

SOURCES OF EVIDENCE
This summary was conducted using methods published by the Joanna Briggs Institute. The summary is based on a literature search combining search terms related to SOSs and wounds. Only studies that used a solution described as super-oxidised on a chronic wound were included in the clinical evidence summary. Searches were conducted in CINAHL, Medline, the Cochrane Library and Google Scholar for evidence published up to December 2019 in English. Levels of evidence for intervention studies are reported in the table below.

BACKGROUND
Super-oxidised solutions are low concentration saltwater that have had an electrical current applied to increase ions in the solution. Super-oxidised solutions contain hypochlorous acid (HOCL) and sodium hypochlorite (NaOCL). However, not all HOCL solutions are super-oxidised. They are naturally acidic due to increased hydrogen ions, but some solutions are further processed to balance the pH (neutral). They may also be referred to as super-oxidised water, or most commonly by product names. Bench research reports that SOSs have antibacterial and antifungal qualities against strains commonly observed in chronic wounds, including antibiotic-resistant bacteria and biofilm based organisms. There is laboratory-based evidence that they reduce inflammatory markers (Level 5).

<table>
<thead>
<tr>
<th>Level 1 Evidence</th>
<th>Level 2 Evidence</th>
<th>Level 3 Evidence</th>
<th>Level 4 Evidence</th>
<th>Level 5 Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1b Systematic review of RCTs and other study designs</td>
<td>Level 2.c Quasi-experimental prospectively controlled study</td>
<td>None</td>
<td>4.c Case series</td>
<td>5.c Bench research and single expert opinion</td>
</tr>
<tr>
<td>1.c RCTs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

§ Super-oxidised solutions in common use include (but are not limited to) Microdacyn®, Dermacyn®, Electromicyn™, Sterilox® and Microcyn®. This information is included to assist health professionals in identifying products as the term ‘super-oxidised solution’ may not be included in labelling. WHAM@Curtin does not endorse any specific products.
CLINICAL EVIDENCE

Reduction in local infection

- A systematic review reporting a range of studies reported that four studies showed SOSs are superior to povidone iodine as an antibiotic therapy, with bacterial clearance achieved after 3 weeks compared to 3.4 to 8.15 weeks for povidone iodine (Level 1).  
- A single-blinded RCT at moderate risk of bias reported quantitative microbial analysis for post-surgical diabetic foot ulcers (n = 40) irrigated daily with either SOS or 50% povidone iodine/saline. The regimens were equally effective in controlling Gram positive and Gram negative bacteria, fungi and methicillin-resistant Staphylococcus aureus (p ≠ not significant for all) (Level 1).  
- In a prospective study at high risk of bias, infected diabetic foot ulcers undergoing surgery (n = 218) the odds ratio for successful reduction in bacterial burden when treated with an SOS compared with povidone iodine was 3.4 (95% confidence interval [CI] 1.7 to 7.0) (Level 2).  
- In a case series at high risk of bias, 19/20 diabetic foot ulcers treated with SOS soaked gauze were cleared of bacterial infection after a maximum of five days of treatment (Level 4).

Improvement in wound healing outcomes

- A systematic review reported that six studies showed healing rate range with SOSs was 6.9% to 65% compared to 50 to 62.5% with povidone iodine. Healing times reported in four studies were 5.1 to 5.3 weeks with SOS compared with 5.16 to 8.7 weeks with povidone iodine (Level 1).  
- A single-blinded RCT at moderate risk of bias showed healing rates for post-surgical diabetic foot ulcers (n = 40) irrigated daily with SOS were superior to those with 50% povidone iodine/saline. Super-oxidised solution was associated with significantly greater percent of the wounds reaching complete healing at six months (90% versus 55% for povidone iodine, p = 0.002). Mean healing time was also faster for SOS (10.5 ± 5.9 weeks versus 16.5 ± 7.1 weeks, p = 0.007) (Level 1).  
- A single-blinded RCT at moderate risk of bias reported outcomes at 20 weeks for infected diabetic foot ulcers (n = 37) treated with SOS compared to treatment with saline. The SOS group experienced significantly better outcomes for reduction of cellullitis (80.9% versus 43.7%, p = 0.01) and advancement of granulation tissue (90.4% versus 62.5%, p = 0.05). Participants in both groups received concurrent systemic antibiotics (Level 1).  
- In an RCT at high risk of bias conducted with infected diabetic ulcers (n = 60), SOS dressings were associated with a significantly greater mean percentage reduction in area compared with povidone iodine dressings (58.90 ± 5.21% versus 40.90 ± 8.76%, p = 0.024) (Level 1).  
- In a single-blinded RCT at high risk of bias, individuals with diabetes-associated wounds received twice daily application of either SOS-soaked or saline-soaked gauze. The SOS treatment was associated with statistically significantly more wounds being downgraded in severity after seven days (p < 0.05) (Level 1).  
- In a prospective comparative study at high risk of bias, infected diabetic foot ulcers receiving surgery (n = 218) the median healing time when treated with an SOS was 43 days compared with 55 days for treatment with povidone iodine (p < 0.0001) (Level 2).  
- Two case series at high risk of bias reported good outcomes with SOS. In the first, chronic wounds of mixed aetiology (n = 13), had a statistically significant reduction in wound surface area (p < 0.01) at one month, with about 53% of the wounds showing 20 to 40% reduction in wound area. In the second case series, there was a 100% limb salvage rate and healing within a mean duration of 6.8 weeks for diabetic foot ulcers treated following surgical management of osteomyelitis (n = 14) (both Level 4).

CONSIDERATIONS FOR USE

The following points could be considered when using SOSs:

- Super-oxidised solutions can be used as a wound irrigant, or can be applied to the wound as a gauze-soaked dressing or can be used as an immersive soak to debride a wound (Levels 1 and 4).  
- A SOS might help manage wound odour. In an RCT, SOS was associated with significant reduction in wound odour compared with saline treatment (100% versus 25%, p = 0.001) (Level 1).  
- A SOS might help manage wound pain. A case series at high risk of bias a SOS was associated with statistically significant reduction in wound pain scores (p < 0.001). The majority of participants had a main score of 5/10 or lower prior to treatment (Level 4).  
- The studies included in this evidence summary reported no major side effects associated with using SOS to treat a chronic wound.

REFERENCES


Coloplast Biatain Literary Awards

Wound Practice & Research, the Australian Journal of Wound Management and Coloplast Australia are pleased to offer three Coloplast Biatain Literary Awards.

These awards are designed to encourage and reward those who publish their wound care clinical experience. The awards acknowledge excellence of original manuscripts, case presentations and clinical research undertaken within Australasia, both novice and advanced.

Each winner of the Coloplast Biatain Literary Award receives $1000 to be used towards future endeavours in wound management. To enter you must be the first-named author of a manuscript published in Wound Practice & Research Journal. Manuscripts must relate to a case study, original research or a literature/clinical practice review, authors are preferably members of Wounds Australia.

Judged by the Editorial Board of Wound Practice & Research annually, one award per category is given based on published articles in the calendar year.

Coloplast manufactures Biatain, Biatain Ag, Biatain Ibu, Biatain Silicone, Biatain Silicone Lite, Biatain Super, Biatain Alginate, Comfeel Plus Transparent and Ulcer dressings which provide integrated solutions in wound healing. Coloplast Wound Care is committed to the development of excellence in wound management practices.